Kepivance, Macugen Approvals Are Quiet Milestones For FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen's Kepivance and Pfizer/Eyetech's Macugen are the first two products approved under the new Pilot 1 "continuous marketing application" program